COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00737373
Recruitment Status : Completed
First Posted : August 19, 2008
Last Update Posted : September 19, 2012
Information provided by (Responsible Party):
Krankenhaus Nordwest

Brief Summary:
In this trial, FLOT will be evaluated as therapy option for elderly patients (>65 years) with advanced gastric cancer in comparison to the well established FLO scheme. The hypothesis is that FLOT is more effective than FLO in elderly patients with acceptable side effects.

Condition or disease Intervention/treatment Phase
Gastric Cancer Adenocarcinoma of the Esophagogastric Junction Drug: Docetaxel Drug: 5-Fluorouracil Drug: Oxaliplatin Drug: folinic acid Phase 2

Detailed Description:

Patients with locally advanced, potentially operable or metastatic gastric cancer or adenocarcinoma of the esophagogastric junction without prior therapy in the palliative setting are treated with:

  • Arm A: FLO
  • Arm B: FLOT

max. 12 cycles

Evaluation of quality of life by standard forms at baseline and then every 2 months until progress of disease. Pharmacogenetic analyses will be done to evaluate a risk profile for platin-based therapies. 140 patients will be treated (70 per arm)

primary endpoint:

  • Response Rate

secondary endpoints:

  • Prospective Validation of a pharmacogenetic risk profile for patients with advanced GC under first-line therapy with platin/docetaxel
  • Evaluation of quality of life
  • safety and tolerability
  • progression free survival (PFS), time to treatment failure (TTF), overall survival (OS)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 143 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile
Study Start Date : August 2007
Actual Primary Completion Date : December 2009
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Arm Intervention/treatment
Experimental: 1
Drug: Docetaxel
50mg/m2 qd15

Drug: 5-Fluorouracil
2600mg/m2 qd15

Drug: Oxaliplatin
85mg/m2 qd15

Drug: folinic acid
200mg/m2 qd15

Active Comparator: 2
Drug: 5-Fluorouracil
2600mg/m2 qd15

Drug: Oxaliplatin
85mg/m2 qd15

Drug: folinic acid
200mg/m2 qd15

Primary Outcome Measures :
  1. response (WHO criteria) [ Time Frame: staging every 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • metastatic or locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction
  • no prior chemotherapy in metastatic state
  • adequate blood and biochemistry parameters

Exclusion Criteria:

  • hypersensitivity for 5-FU, Leucovorin, Oxaliplatin or Docetaxel
  • KHK, cardiomyopathy or cardiac insufficiency
  • malignancy <5 years ago
  • brain metastases
  • severe internal disease or inadequate blood and biochemistry parameters

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00737373

Layout table for location information
Krankenhaus Nordwest
Frankfurt, Germany, 60488
Sponsors and Collaborators
Krankenhaus Nordwest
Layout table for investigator information
Study Chair: Salah Al-Batran, MD Krankenhaus Nordwest
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Krankenhaus Nordwest Identifier: NCT00737373    
Other Study ID Numbers: FLOT65+
First Posted: August 19, 2008    Key Record Dates
Last Update Posted: September 19, 2012
Last Verified: August 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases
Folic Acid
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors